| 7 Octubre 2020 - 10:00am por ABOCA | 12 Noviembre 2026 - 9:34am por ABOCA | ||
|---|---|---|---|
| Cambios a Authorization date | |||
| - | + | 2019-01-07 00:00:00 | |
| Cambios a Reference number | |||
| - | In process | + | 009/05.001.19QV |
| Cambios a Recruitment status | |||
| - | Pending | + | Suspended |
| Cambios a Data sharing plan | |||
| - | + | Not entered | |
| Cambios a Date of first enrollment | |||
| - | 2018-12-10 05:00:00 | + | 2019-01-29 00:00:00 |
| Cambios a Primary outcome(s) | |||
| - | Severity of Irritable Bowel Syndrome-IBS (Reduction of the severity of IBS measured by the Bowel Syndrome Severity Score-IBSSS (Francis) at the end of treatment in each stage respect to baseline value of each one). Measurement time: At baseline, weeks 2, 4, 12 (stage 1 y stage 2) and, week 26 (follow-up at the end of second stage). | + | Percentage reduction in the IBS-SS (Francis) questionnaire score: (To determine the percentage reduction, the change in the total score obtained from the IBS-SS (Francis) questionnaire at week 12 of treatment will be evaluated relative to the baseline value. An individual response will be considered to have occurred if the percentage reduction at 12 weeks (V3) compared to the baseline value (V0) is 30% or greater. Two intermediate assessments are included to determine when a response to treatment first becomes evident and how that response evolves over time.) |
| Cambios a Key secondary outcomes | |||
Related to efficacy:
| Related to efficacy:
| ||
| - | 1. Intensity of pain (Change of the value of this item in the IBSSS (Francis) questionnaire at the end of treatment in each stage respect to baseline value of each one). Measurement time: At baseline, weeks 2, 4, 12 (stage 1 y stage 2) and, week 26 (follow-up at the end of second stage).
| + | 1. Reduction in the IBS-SS (Francis) questionnaire score: (The difference between the total score on the IBS-SS (Francis) questionnaire at the end of the 12-week treatment period and the baseline score will be evaluated. A reduction of at least 50 points in the total score will be considered for the assessment of this secondary efficacy endpoint. Two interim assessments are included to determine when clinical improvement begins to manifest and how it progresses over time.)
|
| - | 2. Intensity of abdominal distension (Change of the value of this item in the IBSSS (Francis) questionnaire at the end of treatment in each stage respect to baseline value of each one). Measurement time: At baseline, weeks 2, 4, 12 (stage 1 y stage 2) and, week 26 (follow-up at the end of second stage).
| + | 2. Improvement in Irritable Bowel Syndrome (IBS) severity: (IBS severity will be assessed using an IBS severity classification based on the total scale score: normal: 0 to < 75; mild: ≥ 75 to < 175; moderate: ≥ 175 to ≤ 300; severe: > 300. An improvement in severity will be considered to have occurred if, by week 12, the initial severity classification has decreased by at least one level.)
|
| - | 3. Changes in bowel habit (Change of the value of this item in the IBSSS (Francis) questionnaire at the end of treatment in each stage respect to baseline value of each one). Measurement time: At baseline, weeks 2, 4, 12 (stage 1 y stage 2) and, week 26 (follow-up at the end of second stage).
| + | 3. Pain intensity (change in the value for this variable from the IBS-SS (Francis) questionnaire at the end of treatment compared to the baseline value). Measurement time points: baseline, weeks 2, 4, and 12, and week 14 (follow-up).
|
| - | 4. Quality of Life (IBS-QOL questionnaire). Measurement time: At baseline and, week 12 (in each stage)
| + | 4. Intensity of abdominal distension: change in the value for this variable from the IBS-SS (Francis) questionnaire at the end of treatment compared to the baseline value. Measurement time points: baseline, weeks 2, 4, 12, and week 14 (follow-up)
|
| - | + | 5. Changes in bowel habits (Change in the score for this variable from the IBSSS questionnaire (Francis) at the end of treatment compared to the baseline value). Measurement time points: baseline, weeks 2, 4, 12, and week 14 (follow-up)
| |
| - | Note: The baseline value of the stage 2 is recorded in the second week of this stage. This week corresponds with the week 14 if both stage are considered in a same timeline.
| + | 6. Quality of Life: (IBS-QOL questionnaire). Measurement time points: at baseline, week 12
|
| - | + | Safety-related:
| |
| - | Related to safety:
| + | 7. Adverse events (AEs) (Incidence of AEs reported by the patient or via laboratory tests, measured as: Occurrence of an AE (Yes, No); Description of the AE (name of the adverse event); Duration of the AE (difference in dates between the onset and resolution of the AE); Intensity of the AE (mild, moderate, severe, life-threatening or disabling AE, or AE resulting in death); Severity of the AE (serious, non-serious); Action taken regarding the study treatment (no change, dose modification, temporary or permanent discontinuation of the study treatment); Outcome of the AE (recovered, improved, persistent, or sequelae); Causal relationship (1. Definite, 2. Highly probable, 3. Probable, 4. Possible, 5. Unrelated, 6. Unknown)). Measurement time points: at baseline, weeks 2, 4, 12, and week 14 (follow-up). |
| - | 5. Adverse events-AE (Reported by the patient and by laboratory tests measured as: Occurrence of an AE (Yes, No); Description of the AE (Name of the adverse event); Duration of the AE (Difference between start and finish of AE); Intensity of the AE (Mild, Moderate, Severe, AE that threatens or incapacitates and AE that causes death); Severity of the AE (Serious/serious, Not serious/not serious); Treatment under study (No changes, Dose modification, Temporary interruption, Definitive interruption of treatment under study); AE result (Recovered, Improved, Persists, Squeals); Causal relationship (1. Definitive 2. Very Likely, 3. Likely, 4. Possible, 5. Unrelated 6. Unknown)). Measurement time: At baseline, weeks 2, 4, 12 (stage 1 y stage 2) and, week 26 (follow-up at the end of second stage). | + | |
| Cambios a Intervention(s) | |||
| - | Stage 1:
| + | Group I (Experimental) - Colilen IBS: 2 capsules of 587 mg by oral route, three times a day, between 30 minutes and 2 hours before meals, for 12 weeks.
|
| - | Group I (Experimental) - Colilen IBS (Batch A): 2 capsules of 587 mg by oral route, three times a day, between 30 minutes and 2 hours before meals, for 12 weeks.
| + | |
Group II (Control)- Placebo: 2 capsules by oral route, three times a day, between 30 minutes and 2 hours before meals, for 12 weeks.
| Group II (Control)- Placebo: 2 capsules by oral route, three times a day, between 30 minutes and 2 hours before meals, for 12 weeks.
| ||
| - | Stage 2:
| + | |
| - | Group I (Experimental) - Colilen IBS (Batch B): 2 capsules of 587 mg by oral route, three times a day, between 30 minutes and 2 hours before meals, for 12 weeks.
| + | |
| - | Group II (Experimental) - Colilen IBS (Batch C): 2 capsules of 587 mg by oral route, three times a day, between 30 minutes and 2 hours before meals, for 12 weeks.
| + | |
| Cambios a Exclusion criteria | |||
9. Patient diagnosed with chronic pancreatitis.
| 9. Patient diagnosed with chronic pancreatitis.
| ||
10. Patient with decompensated intercurrent diseases that, at the discretion of the physician, could endanger the safety of the patient and / or compliance with the study procedures by the patient, such as: metabolic, electrolyte or other disorders.
| 10. Patient with decompensated intercurrent diseases that, at the discretion of the physician, could endanger the safety of the patient and / or compliance with the study procedures by the patient, such as: metabolic, electrolyte or other disorders.
| ||
| - | 11. Patient requiring treatment with antidepressants.
| + | 11.Patient who requires starting treatment with antidepressants and / or steroids.
|
12. Patient who received treatment with antibiotics and / or steroids in the month prior to inclusion in the study.
| 12. Patient who received treatment with antibiotics and / or steroids in the month prior to inclusion in the study.
| ||
13. Patient who in the two weeks prior to inclusion in the study received treatment with drugs not allowed as concomitant therapies.
| 13. Patient who in the two weeks prior to inclusion in the study received treatment with drugs not allowed as concomitant therapies.
| ||
14. Patient who consumes probiotic yogurt.
| 14. Patient who consumes probiotic yogurt.
| ||
| Cambios a Final enrolment number | |||
| - | + | 79 | |
| Cambios a Study completion date | |||
| - | + | 2025-02-05T00:00:00 | |
| Cambios a Target sample size | |||
| - | 176 | + | 140 |
| Cambios a Record Verification Date | |||
| - | 2020/10/07 | + | 2026/11/12 |
| Cambios a Next update date | |||
| - | 2021/10/07 | + | 2027/11/12 |
| Cambios a Scientific title | |||
| - | Phase III clinical trial, prospective randomized, of superiority, to evaluate the efficacy and safety of Colilen IBS vs. placebo in Irritable Bowel Syndrome. Batch comparability study. | + | Phase III clinical trial, prospective randomized, of superiority, to evaluate the efficacy and safety of Colilen IBS vs. placebo in Irritable Bowel Syndrome. |
| Cambios a Source(s) of monetary or material support | |||
| - | Aboca SpA Società Agricola laboratories
| + | Aboca SpA Società Agricola laboratoriesCuban Ministry of Public Health (MINSAP) |
| - | Cuban Ministry of Public Health (MINSAP)
| + | |
| - | + | ||
| Cambios a Results file | |||
| + | sites/default/files/GENERAL INFORMATION OF THE CLINICAL TRIAL_0.pdf | ||
Revisión de 12 Noviembre 2026 - 9:34am